Opko Health Inc

Most Recent

  • uploads///molecule _
    Company & Industry Overviews

    Wall Street Analysts: Mostly Positive on Opko Health in July

    On July 11, Opko Health (OPK) stock closed at $6.01, which represents 126% growth from its 52-week low of $2.66 in March.

    By Daniel Collins
  • uploads///Nephrology
    Company & Industry Overviews

    How Amgen’s Nephrology Drugs Are Positioned after 2Q17?

    In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Rayaldee Is a Key Revenue Driver for Opko Health

    In its third-quarter earnings conference call, Opko Health (OPK) forecasted its total product revenues to fall in the range of $28 million to $32 million in the fourth quarter.

    By Margaret Patrick
  • uploads///rayaldee
    Company & Industry Overviews

    Rayaldee Could Boost Opko Health’s Revenue in 2018 and Beyond

    Opko Health’s (OPK) Rayaldee generated revenues of $3.7 million in the first quarter. Rayaldee had a solid uptake that quarter.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Why Quest Diagnostics’ Five Point Business Strategy Matters in 2016

    If Quest Diagnostics succeeds in implementing its five-point business strategy going forward, it should boost the company’s share price and USMV.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    LabCorp’s Growth Drivers in 1Q16: Organic Growth, Acquisitions

    In 1Q16, LabCorp’s (LH) national clinical laboratory business, LabCorp Diagnostics, accounted for 69.3% of the company’s total revenues.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside Quest Diagnostics’ Growth Restoration Strategy

    Quest Diagnostics has been focusing on developing sales and marketing expertise, increasing esoteric testing, and building relationships with hospitals.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Revenue Growth Initiatives Drove LabCorp’s Performance in 1Q16

    In 1Q16, LabCorp (LH) reported strong revenue and earnings growth due to the effective implementation of multiple strategic initiatives. LabCorp is the world’s leading healthcare diagnostics company.

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI News as of March 16: Mid-Caps Under Pressure

    Given selling pressures, XBI’s 18 mid-cap stocks went down marginally on average, losing 0.4% on March 16. Eight stocks advanced while ten stocks declined.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI on a Downward Slope, but How Steep?

    On March 16, pressure on biotech and healthcare continued, with the SPDR S&P Biotech ETF (XBI) losing another 1.2% that day and closing at $48.31.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.